Executive Summary
Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) are among the most resource-intensive regulatory obligations facing pharmaceutical companies. A single PBRER for a marketed product typically requires 12-20 weeks of effort from a team of 8-15 professionals, costing $500K-$1.2M per report. For companies with portfolios of 10-50 marketed products, the cumulative burden is substantial.
This whitepaper demonstrates how AI-driven automation can reduce PBRER/PSUR preparation time by 70-80%, improve consistency and quality, and enable a shift from reactive document production to proactive safety surveillance. We detail the data pipeline architecture, quality assurance mechanisms, and compliance considerations for automated periodic safety reporting.
1. PSUR/PBRER Regulatory Requirements
The PBRER (known as PSUR in some jurisdictions) is a comprehensive assessment of a product's global benefit-risk balance, required at regular intervals throughout a product's market life. The current regulatory framework is defined by ICH E2C(R2), which establishes the content, format, and analytical expectations for these reports.
1.1 Key ICH E2C(R2) Requirements
The ICH E2C(R2) guideline specifies that a PBRER should contain:
- Worldwide marketing authorization status and regulatory actions taken during the reporting interval
- Estimated exposure data including patient-exposure and patient-time calculations from multiple sources
- Presentation of individual case histories for serious, unlisted, or otherwise noteworthy adverse reactions
- Summary tabulations of adverse reactions from clinical trials and spontaneous sources
- Signal evaluation including new signals identified, ongoing assessments, and closed signals
- Integrated benefit-risk analysis considering new efficacy/effectiveness information alongside the safety profile
- Conclusions and actions including any proposed label changes or risk minimization measures
1.2 Submission Schedules
| Region | Report Type | Frequency | Submission Timeline |
|---|---|---|---|
| EU (EMA) | PSUR | Per EURD list | 70 days after DLP |
| US (FDA) | PBRER | Annual (first 3 years), then triennial | 60 days after anniversary |
| Japan (PMDA) | PSUR | Semi-annual (first 2 years), then annual | 60 days after DLP |
| ICH Harmonized | PBRER | Per birth date cycle | 70 days for single assessment |
DLP = Data Lock Point; EURD = European Union Reference Dates
2. Current Manual Process Pain Points
Despite the critical importance of PBRERs, the preparation process remains largely manual in most organizations, creating significant operational challenges:
Data collection bottleneck: Gathering safety data from multiple global sources (safety database, clinical trial databases, literature, regulatory intelligence) requires coordination across departments and geographies. Data extraction alone can take 4-6 weeks.
Manual narrative writing: Individual case narratives, signal summaries, and the integrated benefit-risk analysis are written manually by medical writers and safety physicians. A single PBRER may contain 50-200 pages of narrative text.
Review and revision cycles: Multi-layered review processes involving safety physicians, regulatory affairs, medical affairs, and senior management typically require 3-5 revision cycles, each adding 1-2 weeks to the timeline.
Inconsistency across products: When different teams prepare PBRERs for different products, inconsistencies in analytical approach, writing style, and depth of assessment are common, creating regulatory risk.
Version control challenges: With multiple contributors and reviewers, maintaining document integrity and tracking changes becomes increasingly complex, particularly when parallel review streams are required to meet deadlines.
3. AI-Driven Automation Approach
ArcaScience's PBRER automation platform addresses each of these pain points through an integrated AI pipeline that automates data collection, analysis, narrative generation, and quality assurance:
Automated data extraction: Direct API connections to safety databases (Argus, ArisG, AERS), clinical trial management systems, and literature databases enable automated data extraction within hours of the data lock point.
AI-generated narratives: Large language models trained on pharmacovigilance writing standards generate draft narratives for case summaries, signal evaluations, and benefit-risk assessments. These drafts are calibrated to match the company's writing conventions and regulatory submission standards.
Automated tabulations: Summary tabulations of adverse reactions by system organ class, seriousness, and outcome are generated automatically with cross-checks against source data for accuracy.
Integrated benefit-risk analysis: The platform automatically updates the product's MCDA-based benefit-risk model with new data from the reporting interval, generating the quantitative benefit-risk section with current evidence.
Intelligent review workflow: AI-assisted review highlights areas requiring expert attention, flags inconsistencies between sections, and ensures compliance with ICH E2C(R2) content requirements.
4. Data Pipeline Architecture
The automation platform operates through a structured data pipeline that ensures data integrity, traceability, and regulatory compliance at every stage:
Point
Extraction
Validation
& Drafting
Review
Assembly
4.1 Data Extraction Layer
The platform connects to source systems through validated API integrations, extracting structured data (case demographics, MedDRA-coded events, reporter information) and unstructured data (case narratives, medical histories). Data are extracted according to predefined specifications that map to PBRER content requirements, ensuring completeness while filtering irrelevant information.
4.2 Data Harmonization
Data from different sources use different coding standards, date formats, and terminology. The harmonization layer standardizes all inputs to a common data model, reconciles duplicates, and applies quality rules to flag potential data quality issues. MedDRA coding is validated and, where necessary, recoded to the current version.
4.3 Analytical Engine
The analytical engine performs all standard PBRER analyses automatically:
- Exposure calculations from multiple data sources (clinical trial subject-years, estimated market exposure from sales/prescription data)
- Incidence rate calculations with confidence intervals for key adverse events
- Disproportionality analyses against reference databases
- Temporal trend analyses comparing current interval to previous intervals
- Subgroup analyses by age, gender, indication, and geographic region
- Signal evaluation using pre-defined criteria and AI-assisted assessment
4.4 Narrative Generation
AI-generated narratives follow templates calibrated to regulatory expectations and company-specific writing standards. The system generates:
- Individual case narratives with appropriate level of clinical detail
- Signal summary narratives with evidence evaluation and assessment conclusions
- Benefit-risk assessment narrative integrating quantitative analysis results
- Executive summary and conclusions sections
5. Quality Assurance and Validation
5.1 Automated Quality Checks
The platform performs over 200 automated quality checks across the generated PBRER, including:
- Data consistency between narrative text and tabulated data
- Completeness verification against ICH E2C(R2) content requirements
- Cross-reference validation between sections
- Terminology consistency (MedDRA terms, product names, dosage forms)
- Regulatory compliance checks for jurisdiction-specific requirements
- Comparison with previous PBRER to identify gaps or inconsistencies in approach
5.2 Human-in-the-Loop Review
While AI automation handles the bulk of data processing and draft generation, expert review remains essential. The platform structures the review process to maximize reviewer efficiency:
- Prioritized review queue: AI highlights sections requiring the most expert attention based on complexity, novelty, and regulatory sensitivity
- Track changes integration: All AI-generated content is clearly marked, with source data references linked for easy verification
- Collaborative review: Multiple reviewers can work simultaneously on different sections with real-time conflict detection
6. Compliance with ICH E2C(R2)
The platform is designed from the ground up for ICH E2C(R2) compliance, with built-in safeguards at every stage:
| ICH E2C(R2) Requirement | Platform Compliance Mechanism |
|---|---|
| Worldwide marketing authorization status | Automated extraction from regulatory intelligence databases, with manual verification step |
| Actions taken for safety reasons | Regulatory action tracking module with audit trail |
| Estimated exposure | Multi-source exposure calculation engine with documented methodology |
| Summary tabulations | Automated generation from validated safety database queries |
| Signal and risk evaluation | Integrated signal detection and evaluation workflow with complete documentation |
| Benefit-risk analysis | MCDA-based quantitative BRA with automated narrative generation |
| Audit trail | Full traceability from source data to final document, including all AI processing steps |
7. ROI Analysis
preparation time
(average)
compliance rate
| Cost Category | Manual Process | ArcaScience Automated | Savings |
|---|---|---|---|
| Data collection & extraction | $120K (4-6 weeks) | $15K (1-2 days) | 87% |
| Analysis & tabulations | $95K (3-4 weeks) | $10K (automated) | 89% |
| Narrative writing | $180K (4-6 weeks) | $45K (AI draft + expert review) | 75% |
| Review cycles | $150K (3-4 weeks) | $50K (1-2 weeks) | 67% |
| QC & finalization | $55K (1-2 weeks) | $20K (automated QC + final review) | 64% |
| Total per PBRER | $600K-$1.2M | $140K-$320K | 70-75% |
For a company with 15 marketed products requiring annual or semi-annual PBRERs, the annual savings from automation are estimated at $6-10 million, with additional value from improved quality, reduced regulatory risk, and reallocation of pharmacovigilance professionals to higher-value activities such as signal evaluation and risk management.
Transform Your Periodic Safety Reporting
Learn how ArcaScience can reduce your PBRER preparation time by 75% while improving quality and compliance.